Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer

Lucy J Schmidt; Donald J Tindall

doi:10.1016/j.jsbmb.2010.09.003

Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer

J Steroid Biochem Mol Biol. 2011 May;125(1-2):32-8. doi: 10.1016/j.jsbmb.2010.09.003. Epub 2010 Sep 29.

Authors

Lucy J Schmidt¹, Donald J Tindall

Affiliation

¹ Department of Urology Research, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, United States.

PMID: 20883781
DOI: 10.1016/j.jsbmb.2010.09.003

Abstract

Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.

Publication types

Review

MeSH terms

5-alpha Reductase Inhibitors / chemistry
5-alpha Reductase Inhibitors / therapeutic use*
Azasteroids / chemistry
Azasteroids / therapeutic use
Clinical Trials as Topic*
Dutasteride
Finasteride / chemistry
Finasteride / therapeutic use
Humans
Male
Molecular Structure
Prostatic Hyperplasia / drug therapy*
Prostatic Neoplasms / drug therapy*

Substances

5-alpha Reductase Inhibitors
Azasteroids
Finasteride
Dutasteride